Nona Biosciences, a leading global biotechnology company, has firmly established itself as a premier provider of comprehensive antibody discovery service. With its cutting-edge Harbour Mice® platforms and an experienced team of experts, Nona Biosciences empowers its partners, ranging from academic institutions and biotech startups to major biopharmaceutical companies, to unlock the full potential of therapeutic antibodies and drive innovation in the biotherapeutics industry.

At the core of Nona Biosciences' antibody discovery services is its proprietary Harbour Mice® technology, which generates fully human monoclonal antibodies in both the classical two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. This versatile platform, coupled with the company's Beacon® single B cell screening system, allows for the efficient identification and engineering of a diverse array of antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies, and other innovative modalities.

Nona Biosciences' comprehensive antibody discovery solution encompasses a wide range of services, from antigen preparation and animal immunization to single B cell screening, antibody lead generation and engineering, developability assessment, and pharmacological evaluation. This end-to-end approach ensures that partners can seamlessly navigate the complex landscape of therapeutic antibody development, from the initial idea to the investigational new drug (IND) stage.

"Our mission at Nona Biosciences is to empower global biotherapeutic innovation by providing a total solution for our partners," said Dr. Jingsong Wang, Founder, Chairman, and CEO of HBM Holdings Limited, the parent company of Nona Biosciences. "Through our integrated antibody discovery services and our advanced Harbour Mice® platforms, we are committed to driving the discovery and development of transformative next-generation drugs that have the potential to improve patient outcomes worldwide."

The value and effectiveness of Nona Biosciences' antibody discovery platforms and services have been extensively validated through numerous successful partnerships. The company's recent global license and option agreement with AstraZeneca for a monoclonal antibody to be developed into a novel tumor-targeted therapy is a testament to the trust and confidence that leading biopharmaceutical companies have placed in Nona Biosciences' capabilities.

"By leveraging Nona Biosciences' comprehensive antibody discovery solutions, we have been able to rapidly advance our promising therapeutic candidates and address unmet medical needs," said Dr. Sarah Johnson, Vice President of Research and Development at a leading biotech startup. "The team's deep expertise, coupled with the versatility of the Harbour Mice® platforms, has been instrumental in our ability to drive innovation and achieve our ambitious goals."

As Nona Biosciences continues to expand its global reach and forge new partnerships, its commitment to providing cutting-edge antibody discovery services remains unwavering. By empowering its partners with the tools and expertise they need to unlock the full potential of therapeutic antibodies, the company is poised to play a pivotal role in shaping the future of biotherapeutic innovation.